4-Fluor-1,3-diisopropyl-benzol | 1426-87-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-Fluor-1,3-diisopropyl-benzol
• 英文别名: 2,4-Diisopropylfluorobenzene；1-fluoro-2,4-di(propan-2-yl)benzene
• CAS: 1426-87-5
• 化学式: C₁₂H₁₇F
• 分子量: 180.265
• InChiKey: AHARHPAMHWFYLJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  氟苯 、 三聚丙烯 在 boron trifluoride phosphoric acid 作用下， 生成 4-Fluor-1,3-diisopropyl-benzol
  参考文献：
  名称：

  Vakhtin,V.G.; Zavgorodnii,S.V., Journal of general chemistry of the USSR, 1960, vol. 30, p. 116 - 118

  摘要：

  DOI：

文献信息

• BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20160333009A1

  公开（公告）日：2016-11-17

  The present disclosure provides indoleamine 2,3-dioxygenase 1 (IDOL) inhibitors of Formula I: or pharmaceutically acceptable salts thereof, in which X, L, n, m, R 1 , R 2a , R 2b , R n , R m , and R t are as defined herein, as well as pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using the same to treat conditions mediated by IDO1.

  本公开提供了式I的吲哌酮2,3-二氧化酶1（IDOL）抑制剂： 或其药学上可接受的盐，其中X、L、n、m、R 1 、R 2a 、R 2b 、R n 、R m 和R t 如本文所定义，以及包括式I化合物的药物组合物，或其药学上可接受的盐，并使用这些方法来治疗由IDO1介导的疾病。
• NOVEL COMPOUND HAVING ABILITY TO INHIBIT 11B-HSD1 ENZYME OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT
  申请人：AHN-GOOK PHARMACEUTICAL CO., LTD.

  公开号：US20150210635A1

  公开（公告）日：2015-07-30

  The present invention relates to a novel compound or a pharmaceutically acceptable salt thereof inhibiting 11β-HSD1 enzyme activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. Since the compound of the present invention selectively inhibits the activity of 11β-HSD1 (11β-Hydroxysteroid dehydrogenase type 1), the compound of the invention can be effectively used as a therapeutic agent for the treatment of diseases caused by the over-activation of 11β-HSD1 such as non-insulin dependent type II diabetes, insulin resistance, obesity, lipid disorder, metabolic syndrome, and other diseases or condition mediated by the excessive activity of glucocorticoid.

  本发明涉及一种新颖的化合物或其药物可接受的盐，该化合物抑制11β-HSD1酶活性，其制备方法，以及包含该化合物作为活性成分的药物组合物。由于本发明的化合物选择性地抑制11β-HSD1（11β-羟基类固醇脱氢酶1型）的活性，因此本发明的化合物可以有效地用作治疗由11β-HSD1过度激活引起的疾病的治疗剂，例如非胰岛素依赖型2型糖尿病、胰岛素抵抗、肥胖、脂质紊乱、代谢综合征以及其他由糖皮质激素过度活动介导的疾病或状况。
• [EN] PROTEASOME INHIBITORS<br/>[FR] INHIBITEURS DE PROTÉASOMES
  申请人：MILLENNIUM PHARM INC

  公开号：WO2009020448A1

  公开（公告）日：2009-02-12

  The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

  本发明提供了作为蛋白酶体抑制剂有用的新化合物。该发明还提供了包括本发明化合物的药物组合物，以及在治疗各种疾病中使用这些组合物的方法。
• HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS
  申请人：INTEGRAL BIOSCIENCES PRIVATE LIMITED

  公开号：US20200206233A1

  公开（公告）日：2020-07-02

  The present disclosure relates generally to compounds useful in treatment of conditions associated with mutant isocitrate dehydrogenase (mt-IDH), particularly mutant IDH1 enzymes. Specifically, the present invention discloses compound of formula (IA), which exhibits inhibitory activity against mutant IDH1 enzymes. Method of treating conditions associated with excessive activity of mutant IDH1 enzymes with such compound is disclosed. Uses thereof, pharmaceutical composition, and kits are also disclosed.

  本公开涉及一般用于治疗与突变异柠檬酸脱氢酶（mt-IDH）相关的疾病的化合物，特别是突变IDH1酶。具体地，本发明揭示了式（IA）的化合物，该化合物对突变IDH1酶表现出抑制活性。还公开了使用该化合物治疗与突变IDH1酶过度活性相关的疾病的方法。此外，还公开了其用途、药物组合物和试剂盒。
• AMINOTHIAZINE OR AMINOOXAZINE DERIVATIVE HAVING AMINO LINKER
  申请人：Masui Moriyasu

  公开号：US20120238557A1

  公开（公告）日：2012-09-20

  The present invention provide a medicament for treating the diseases induced by production, secretion or deposition of amyloid-β proteins, for example, a compound of the following formula (I) wherein R 1 , R 2a , R 2b , R 3 , R 4 , R 5 , X, L 1 , L 2 , A, ring B and the dotted line are defined in the specification, its pharmaceutically acceptable salt or a solvate thereof.

  本发明提供了一种治疗由淀粉样蛋白β的产生、分泌或沉积引起的疾病的药物，例如以下式(I)的化合物，其中R1、R2a、R2b、R3、R4、R5、X、L1、L2、A、环B和虚线在规范中有定义，其药学上可接受的盐或溶剂化合物。